Ardent Health, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 6, 2025 and accepted by EDGAR at Aug 6, 2025, 16:37 ET.
Management's discussion and analysis
As filed, 86,660 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
RESULTS OF OPERATIONS
Management's discussion and analysis of our financial condition and results of operations should be read in conjunction with
our interim unaudited condensed consolidated financial statements and related notes contained elsewhere in this Quarterly
Report on Form 10-Q for the quarter ended June 30, 2025 (this "Quarterly Report") and our audited consolidated financial
statements for the year ended December 31, 2024 and related notes contained in the Annual Report. The following discussion
includes forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never
materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-
looking statements. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties
that could impact our business. In particular, we encourage you to review the risks and uncertainties described in the section
titled “Risk Factors” included in the Annual Report. These risks and uncertainties could cause actual results to differ
materially from those projected in forward-looking statements contained in this Quarterly Report or implied by past results
and trends. Our historical results are not necessarily indicative of the results that may be expected for any period in the
future, and our interim results are not necessarily indicative of the results we expect for the full fiscal year or any other
period.
Unless otherwise indicated, all relevant financial and statistical information included herein relates to our consolidated
operations. Additionally, unless the context indicates otherwise, Ardent Health, Inc. and its affiliates are referred to in this
section as “we,” “our,” or “us.”
Forward-Looking Statements
This Quarterly Report may contain certain “forward-looking statements,” as that term is defined in the U.S. federal securities
laws. These forward-looking statements include, but are not limited to, statements other than statements of historical facts,
including, among others, statements relating to our future financial performance, our business prospects and strategy,
anticipated financial position, liquidity and capital needs, the industry in which we operate and other similar matters. Words
such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,”
“may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often
identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the
forward-looking statements. Factors, risks, and uncertainties that could cause actual outcomes and results to be materially
different from those contemplated include, among others: (1) general economic and business conditions, both nationally and
in the regions in which we operate, including the impact of challenging macroeconomic conditions and inflationary pressures,
current geopolitical instability, and impacts from the imposition of, or changes in, tariffs, as well as the potential impact on us
of uncertain political, financial, credit and capital conditions; (2) possible reductions or other changes in Medicare, Medicaid
and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs or state directed
payments, that could have an adverse effect on our revenues and business; (3) reduction in the reimbursement rates paid by
commercial payors, increased reimbursement denials or payment delays by commercial payors, our inability to retain and
negotiate favorable contracts with private third party payors, or an increasing volume of uninsured or underinsured patients;
(4) effects of changes in healthcare policy or legislation, including the One Big Beautiful Bill Act (the "OBBBA") and any
other reforms that have or may be undertaken by the current presidential administration, and legal and regulatory restrictions
on our hospitals that have physician owners; (5) the ability to achieve operating and financial targets, develop and execute
mitigation plans to offset to the extent possible impacts from the OBBBA, the scheduled expiration of temporary enhanced
subsidies for individuals eligible to purchase insurance coverage through health insurance marketplaces and imposition of
tariffs, attain expected levels of patient volumes and revenues, and control the costs of providing services; (6) security threats,
catastrophic events and other disruptions affecting our, our service providers’ or our joint venture (“JV”) partners’
information technology and related systems, which have adversely affected, and could in the future adversely affect, our
relationships with patients and business partners and subject us to legal claims and liabilities, reputational harm and business
disruption and adversely affect our financial condition; (7) the highly competitive nature of the healthcare industry and
continued industry trends towards clinical transparency and value-based purchasing may impact our competitive position; (8)
inability to recruit and retain quality physicians, as well as increasing cost to contract with hospital-based physicians; (9)
changes to physician utilization practices and treatment methodologies and other factors outside our control that impact
demand for medical services and may reduce our revenues and ability to grow profitability; (10) the effects related to the
sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and
the potential for future deficit reduction legislation; (11) continued industry trends toward value-based purchasing, third party
payor consolidation and care coordination among healthcare providers; (12) inability to successfully complete acquisitions or
strategic JVs or inability to realize all of the anticipated benefits; (13) liabilities because of professional liability and other
claims brought against our hospitals, physician practices, outpatient facilities or other business operations; (14) exposure to
certain risks and uncertainties by the JVs through which we conduct a significant portion of our operations, including
23
anticipated synergies, of past acquisitions and the risk that transactions may not receive necessary government clearances;
(15) failure to obtain drugs and medical supplies at favorable prices or sufficient volumes; (16) operational, legal and
financial risks associated with outsourcing functions to third parties; (17) our facilities are heavily concentrated in Texas and
Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states; (18)
negative impact of severe weather, climate change, and other factors beyond our control, which could restrict patient access
to care or cause one or more facilities to close temporarily or permanently; (19) risks related to the Ventas Master Lease and
its restrictions and limitations on our business; (20) the impact of our significant indebtedness and the ability to refinance
such indebtedness on acceptable terms; (21) our failure to comply with complex laws and regulations applicable to the
healthcare industry or to adjust our operations in response to changing laws and regulations; (22) the impact of governmental
claims or governmental investigations, payor audits and litigation brought against our hospitals, physician practices,
outpatient facilities or other business operations; (23) actual or perceived failures to comply with applicable data protection,
privacy and security laws, regulations, standards and other requirements; (24) the impact of a deterioration of public health
conditions associated with a future pandemic, epidemic or outbreak of infectious disease; (25) inability to or delay in
building, acquiring, selling, renovating or expanding our healthcare facilities; (26) failure to comply with federal and state
laws relating to Medicare and Medicaid enrollment, permit, licensing and accreditation requirements; (27) the results of our
efforts to use technology, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an
enhanced patient experience; (28) our status as a controlled company; (29) conflicts of interest between our controlling
stockholder and other holders of our common stock; and (30) other risk factors described in our filings with the SEC,
including the Annual Report.
We caution you that the foregoing list may not contain all of the risks and uncertainties that may affect the forward-looking
statements made in this Quarterly Report. You should not rely upon forward-looking statements as predictions of future
events.
The forward-looking statements in this Quarterly Report are based on management’s current beliefs, expectations, and
projections about future events and trends affecting our business, results of operations, financial condition, and prospects.
These statements are subject to risks, uncertainties, and other factors described in the “Risk Factors” section of the Annual
Report. We operate in a competitive and rapidly changing environment where new risks and uncertainties can emerge,
making it impossible to predict all potential impacts on our forward-looking statements. Consequently, actual results may
differ materially from those described. The forward-looking statements pertain only to the date they are made, and we do not
undertake any obligation to update them to reflect new information or events unless required by law. You are advised not to
place undue reliance on these statements and to consult any additional disclosures we may provide through our other filings
with the SEC, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Overview
Ardent is a leading provider of healthcare services in the United States, operating in eight growing mid-sized urban markets
across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas. We deliver care through a system of 30
acute care hospitals and approximately 280 sites of care with 1,875 employed and affiliated providers as of June 30, 2025.
Affiliated providers, which have increased 4.7% compared to June 30, 2024, are physicians and advanced practice providers
with whom we contract for services through a professional services agreement or other independent contractor agreement.
We hold a leading position in a majority of our markets, and we believe we are one of the leading healthcare systems based
on market share and our integrated network of hospitals, ambulatory facilities, and physician practices. We operate either
independently or in partnership with premier academic medical centers, large not-for-profit hospital systems, community
physicians, and a community foundation through our well-established and differentiated JV model. Collectively, we operate
with a consumer-centric approach to caring for our patients and our communities. Our strategic JV partners offer us
significant advantages, including expanded access points, clinical talent availability, local brand recognition, and scale that
enable us to accelerate market penetration. We believe that we help our partners enhance their network and regional presence
through our operational acumen. We strive to strengthen clinical services, drive operating improvements, and centrally
manage operations to optimize hospital performance and enhance patient care. In each of these partnerships, we are the
majority owner and serve as the day-to-day operator.
Recent Developments
Regulatory Update
On July 4, 2025, Congress passed the OBBBA, its budget reconciliation act for fiscal year 2025. The OBBBA includes
provisions that may impact our financial performance and may substantially modify certain state and federal statutes and
regulations to which our operations are subject. The OBBBA provisions that may impact us have varying effective dates, and
24
we are working to analyze their potential impact and timing. We are unable to predict whether or how future legislation,
rulemaking, or judicial action will impact implementation of the OBBBA. Of particular relevance to us, the OBBBA may
reduce the federal government’s overall Medicaid expenditures and tighten Medicaid eligibility requirements. The law limits
eligibility for Medicaid by imposing work or community engagement requirements for adults under 65 years old in Medicaid
expansion states, including states with waiver-based expansions, subject to limited exceptions, and requires eligibility
redeterminations at least every six months for the Medicaid expansion state population. State compliance is required by
December 31, 2026.
In addition, the OBBBA includes significant changes to Medicaid funding mechanisms by restricting federal matching funds
received by state Medicaid programs. The law prohibits states from establishing new provider assessments or taxes, or
increasing the rates of existing provider assessments, for state fiscal years beginning after October 1, 2026, while also
limiting the structure and application of such assessments. The OBBBA also directs the Department of Health and Human
Services to revise regulations governing state directed payment program arrangements to cap total payment rates paid by
Medicaid managed care organizations for certain services at Medicare payment rates instead of average commercial rates and
imposed lower caps in Medicaid expansion states. The revised regulations apply to state directed payment programs
established on or after July 4, 2025 unless the program meets certain grandfathering criteria. The OBBBA provides that
payments under grandfathered programs will be reduced beginning January 1, 2028.
Because our facilities rely in part on reimbursement from federal health care programs, including Medicaid, for the
reimbursement of services rendered, these changes may have a negative impact on our financial performance. Ongoing
budgetary uncertainties and continued efforts to reduce the federal deficit may result in further payment reductions to both
Medicaid and Medicare programs.
In addition to changes made to federal healthcare programs, the OBBBA contains policy changes that are expected to
decrease the number of individuals who obtain health insurance from Affordable Care Act marketplace exchanges. For
example, the OBBBA effectively ends automatic renewals of coverage by requiring pre-enrollment verification of eligibility
and restricts subsidized marketplace coverage based on immigration status.
Urgent Care Acquisitions
On January 1, 2025, we completed the acquisitions of certain assets and operations of 18 urgent care clinics in New Mexico
and Oklahoma for a combined purchase price of $27.5 million. The consideration transferred on December 31, 2024,
consisted solely of cash. Upon closing of the acquisitions, approximately $4.1 million was placed into escrow to cover
potential working capital adjustments and to secure certain indemnification obligations pursuant to the terms of the purchase
agreements. This escrow amount is included in the total purchase consideration of $27.5 million. Most of the combined
purchase price for assets and operations acquired was recorded as goodwill with an immaterial portion allocated to
identifiable assets acquired and liabilities assumed. The fair values of assets and liabilities recorded as of June 30, 2025
related to these acquisitions are provisional and will be finalized at the close of the measurement period.
Term Loan B Facility Repricing
On September 18, 2024, we executed an amendment to reprice our Term Loan B Facility credit agreement (the "Term Loan
B Credit Agreement"). The repricing reduced the applicable interest rate by 50 basis points from Term SOFR (as defined in
the Term Loan B Credit Agreement) plus 3.25% to Term SOFR plus 2.75% and from the base rate plus 2.25% to the base
rate plus 1.75% and it eliminated the credit spread adjustment. No modifications were made to the maturity of the loans as a
result of the repricing and all other terms were substantially unchanged.
Initial Public Offering and Corporate Conversion
On July 19, 2024, we completed an IPO of 12,000,000 shares of our common stock, at a public offering price of $16.00 per
share for aggregate gross proceeds of $192.0 million and net proceeds of approximately $181.4 million after deducting
underwriting discounts and commissions of approximately $10.6 million. The IPO provided the underwriters with an option
to purchase up to an additional 1,800,000 shares of our common stock, which was fully exercised by the underwriters, and,
on July 30, 2024, we issued 1,800,000 additional shares of common stock at $16.00 per share for additional net proceeds of
approximately $27.2 million, after deducting underwriting discounts and commissions of approximately $1.6 million. Our
common stock is listed on the New York Stock Exchange under the symbol "ARDT".
25
On July 17, 2024, in connection with the IPO and immediately prior to the effectiveness of our Registration Statement on
Form S-1, we converted from a Delaware limited liability company into a Delaware corporation by means of a statutory
conversion (the "Corporate Conversion") and changed our name to Ardent Health Partners, Inc. As a result of the Corporate
Conversion, the outstanding limited liability company membership units and vested profits interest units were converted into
120,937,099 shares of common stock and outstanding unvested profits interest units were converted into 2,848,027 shares of
restricted common stock. Immediately following the Corporate Conversion, ALH Holdings, LLC, a subsidiary of Ventas, Inc.
("Ventas"), contributed all of its outstanding common stock in AHP Health Partners, Inc. ("AHP Health Partners"), our direct
subsidiary, to Ardent Health Partners, Inc. in exchange for 5,178,202 shares of common stock of Ardent Health Partners, Inc.
(the "ALH Contribution"). The Corporate Conversion and the ALH Contribution have been retrospectively applied to prior
periods herein for the purposes of calculating basic and diluted net income per share. Our certificate of incorporation
authorizes 750,000,000 shares of common stock and 50,000,000 shares of preferred stock, each with a $0.01 par value per
share.
ABL Credit Agreement Amendment and Term Loan B Facility Prepayment
On June 26, 2024, we executed an amendment to our ABL Credit Agreement to increase the revolving commitment by
$100.0 million to $325.0 million and extend the maturity date to June 26, 2029. Concurrent with the execution of this
amendment on June 26, 2024, we also prepaid $100.0 million of the outstanding principal on our Term Loan B Facility. The
$100.0 million prepayment was applied in direct order of maturities of future payments, and no modification was made to the
Term Loan B Facility as a result of this prepayment.
Key Factors Impacting Our Results of Operations
Staffing and Labor Trends
Our operations are dependent on the efforts, abilities and experience of our management and medical support personnel, such
as nurses, pharmacists and lab technicians, as well as our physicians. We compete with other healthcare providers in
recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our
hospitals and other facilities, including nurses and other non-physician healthcare professionals. At times, the availability of
nurses and other medical support personnel has been a significant operating issue for healthcare providers, including at
certain of our facilities. The impact of labor shortages across the healthcare industry may result in other healthcare facilities,
such as nursing homes, limiting admissions, which may constrain our ability to discharge patients to such facilities and
further exacerbate the demand on our resources, supplies and staffing.
We contract with various third parties who provide hospital-based physicians. Third party providers of hospital-based
physicians, including those with whom we contract, have experienced significant disruption in the form of regulatory
changes, including those stemming from enactment of the No Surprises Act, challenging labor market conditions resulting
from a shortage of physicians and inflationary wage-related pressures, as well as increased competition through consolidation
of physician groups. In some instances, providers of outsourced medical specialists have become insolvent and unable to
fulfill their contracts with us for providing hospital-based physicians. The success of our hospitals depends in part on the
adequacy of staffing, including through contracts with third parties. If we are unable to adequately contract with providers, or
the providers with whom we contract become unable to fulfill their contracts, our admissions may decrease, and our operating
performance, capacity and growth prospects may be adversely affected. Further, our efforts to mitigate the potential impact
on our business from third party providers who are unable to fulfill their contracts to provide hospital-based physicians,
including through acquisitions of outsourced medical specialist businesses, employment of physicians and re-negotiation or
assumption of existing contracts, may be unsuccessful. These developments with respect to providers of outsourced medical
specialists, and our inability to effectively respond to and mitigate the potential impact of such developments, may disrupt our
ability to provide healthcare services, which may adversely impact our business, financial condition and results of operations.
We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we
operate. In some of our markets, employers across various industries have increased minimum wages, which has created
more competition and, in some cases, higher labor costs for this sector of employees.
Seasonality
We typically experience higher patient volumes and revenue in the fourth quarter of each year in our acute care facilities. We
typically experience such seasonal volume and revenue peaks because more people generally become ill during the winter
months, which in turn results in significant increases in the number of patients we treat during those months. In addition,
26
revenue in the fourth quarter is also impacted by increased utilization of services due to annual deductibles, which are not
usually met until later in the year, and patient utilization of their healthcare benefits before they expire at year-end.
Inflation
The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor
shortages occur in the marketplace. In addition, our suppliers pass along rising costs to us in the form of higher prices. We
have implemented cost control measures in an attempt to curb increases in operating costs and expenses. We have generally
offset increases in operating costs by increasing reimbursement for services, expanding services and reducing costs in other
areas. However, we cannot predict our ability to cover or offset future cost increases, particularly any increases in our cost of
providing health insurance benefits to our employees.
Geographic Data
The information below provides an overview of our operations in certain markets as of June 30, 2025.
Texas. We operated 13 acute care hospital facilities (including one managed hospital that is owned by The University of
Texas Health Science Center at Tyler, an affiliate of The University of Texas System) with 1,436 licensed beds that serve the
areas of Tyler, Amarillo and Killeen, Texas. For the six months ended June 30, 2025, we generated 36.1% of our total
revenue in the Texas market.
Oklahoma. We operated eight acute care hospital facilities with 1,173 licensed beds that serve the Tulsa, Oklahoma area. For
the six months ended June 30, 2025, we generated 23.5% of our total revenue in the Oklahoma market.
New Mexico. We operated five acute care hospital facilities with 619 licensed beds that serve the areas of Albuquerque and
Roswell, New Mexico. For the six months ended June 30, 2025, we generated 17.2% of our total revenue in the New Mexico
market.
New Jersey. We operated two acute care hospital facilities with 476 licensed beds that serve the areas of Montclair and
Westwood, New Jersey. For the six months ended June 30, 2025, we generated 10.1% of our total revenue in the New Jersey
market.
Other Industry Trends
The demand for healthcare services continues to be impacted by the following trends:
- A growing focus on healthcare spending by consumers, employers and insurers, who are actively seeking lower-cost
care solutions;
- A shift in patient volumes from inpatient to outpatient settings due to technological advancements and demand for
care that is more convenient, affordable and accessible;
- The growing aged population, which requires greater chronic disease management and higher-acuity treatment; and
- Ongoing consolidation of providers and insurers across the healthcare industry.
Additionally, the healthcare industry, particularly acute care hospitals, continues to be subject to ongoing regulatory
uncertainty. Changes in federal or state healthcare laws, regulations, including the imposition of, or changes in, tariffs,
funding policies or reimbursement practices, especially those involving reductions to government payment rates or
limitations on what providers may charge, could significantly impact future revenue and operations. For example, the No
Surprises Act prohibits providers from charging patients an amount beyond the in-network cost sharing amount for services
rendered by out-of-network providers, subject to limited exceptions. For services for which balance billing is prohibited, the
No Surprises Act includes provisions that may limit the amounts received by out-of-network providers from health plans.
Any reduction in the rates that we can charge or amounts we can receive for our services will reduce our total revenue and
our operating margins.
27
Results of Operations
Revenue and Volume Trends
Our revenue depends upon inpatient occupancy levels, ancillary services and therapy programs ordered by physicians and
provided to patients, the volume of outpatient procedures and the charges and negotiated payment rates for such services.
Total revenue is comprised of net patient service revenue and other revenue. We recognize patient service revenue in the
period in which we provide services. Patient service revenue includes amounts we estimate to be reimbursable by Medicare,
Medicaid and other payors under provisions of cost or prospective reimbursement formulas in effect. The amounts we receive
from these payors are generally less than the established billing rates, and we report patient service revenue net of these
differences (contractual adjustments) at the time we render the services. We also report patient service revenue net of the
effects of other arrangements where we are reimbursed for services at less than established rates, including certain self-pay
adjustments provided to uninsured patients. We also record estimated implicit price concessions (based primarily on
historical collection experience) related to uninsured accounts to record self-pay revenue at the estimated amount expected to
be collected.
Total revenue — Total revenue for the three months ended June 30, 2025 increased $174.4 million, or 11.9%, compared to
the same prior year period. The increase in total revenue for the three months ended June 30, 2025 consisted of an increase in
net patient service revenue per adjusted admission of 10.2% and an increase in adjusted admissions of 1.6%, which reflected
growth in admissions and emergency room visits of 6.6% and 0.2%, respectively, partially offset by a decrease in total
surgeries of 0.2%. The increase in net patient service revenue per adjusted admission was primarily attributable to an increase
in supplemental program revenue and reimbursement rates compared to the same prior year period.
Total revenue for the six months ended June 30, 2025 increased $232.5 million, or 8.0%, compared to the same prior year
period. The increase in total revenue for the six months ended June 30, 2025 consisted of an increase in net patient service
revenue per adjusted admission of 5.7% and an increase in adjusted admissions of 2.2%, which reflected growth in
admissions and emergency room visits of 7.1% and 1.3%, respectively, partially offset by a decrease in total surgeries of
0.4%. The increase in net patient service revenue per adjusted admission was primarily attributable to increased supplemental
program revenue and reimbursement rates compared to the same prior year period.
A key competitive strength and a significant component of our growth strategy has been our well-established and
differentiated JV model, which has resulted in partnerships with premier academic medical centers, large not-for-profit
hospital systems, community physicians, and a community foundation. During the three months ended June 30, 2025 and
2024, total revenue related to these entities was $460.0 million and $435.2 million, respectively, which represented 28.0%
and 29.6%, respectively, of our total revenue for such periods. During the six months ended June 30, 2025 and 2024, total
revenue related to these entities was $888.6 million and $851.1 million, respectively, which represented 28.3% and 29.2%,
respectively, of our total revenue for such periods.
The following table provides the sources of our total revenue by payor:
| Three Months Ended June 30, 2025 | 2024 | Six Months Ended June 30, 2025 | 2024 | |
|---|---|---|---|---|
| Medicare | 39.1% | 39.3% | 39.5% | 39.4% |
| Medicaid | 9.7% | 10.6% | 9.9% | 10.7% |
| Other managed care | 44.0% | 43.1% | 43.6% | 42.9% |
| Self-pay and other | 5.6% | 5.3% | 5.4% | 5.4% |
| Net patient service revenue | 98.4% | 98.3% | 98.4% | 98.4% |
| Other revenue | 1.6% | 1.7% | 1.6% | 1.6% |
| Total revenue | 100.0% | 100.0% | 100.0% | 100.0% |
28
Operating Results Summary for the Three Months Ended June 30, 2025
The following table sets forth the consolidated results of our operations expressed in dollars and as a percentage of total
revenue for the periods presented.
(Unaudited, dollars in thousands)
| Three Months Ended June 30, 2025 Amount% | 2024 Amount% | |||
|---|---|---|---|---|
| Total revenue | $1,645,280 | 100.0% | $1,470,920 | 100.0% |
| Expenses: | ||||
| Salaries and benefits | 671,697 | 40.8% | 624,058 | 42.4% |
| Professional fees | 297,012 | 18.1% | 271,903 | 18.5% |
| Supplies | 270,639 | 16.4% | 259,391 | 17.6% |
| Rents and leases | 27,825 | 1.7% | 24,986 | 1.7% |
| Rents and leases, related party | 37,819 | 2.3% | 36,965 | 2.5% |
| Other operating expenses | 163,698 | 10.0% | 115,319 | 7.9% |
| Interest expense | 14,729 | 0.9% | 18,160 | 1.2% |
| Depreciation and amortization | 39,309 | 2.4% | 36,312 | 2.5% |
| Loss on extinguishment and modification of debt | — | 0.0% | 1,898 | 0.1% |
| Other non-operating losses (gains) | 560 | 0.0% | (255) | 0.0% |
| Total operating expenses | 1,523,288 | 92.6% | 1,388,737 | 94.4% |
| Income before income taxes | 121,992 | 7.4% | 82,183 | 5.6% |
| Income tax expense | 26,291 | 1.6% | 15,222 | 1.0% |
| Net income | 95,701 | 5.8% | 66,961 | 4.6% |
| Net income attributable to noncontrolling interests | 22,751 | 1.4% | 24,191 | 1.7% |
| Net income attributable to Ardent Health, Inc. | $72,950 | 4.4% | $42,770 | 2.9% |
Operating Results Summary for the Six Months Ended June 30, 2025
The following table sets forth, for the periods indicated, the consolidated results of our operations expressed in dollars and as
a percentage of total revenue.
(Unaudited, dollars in thousands)
| Six Months Ended June 30, 2025 Amount% | 2024 Amount% | |||
|---|---|---|---|---|
| Total revenue | $3,142,514 | 100.0% | $2,909,966 | 100.0% |
| Expenses: | ||||
| Salaries and benefits | 1,329,349 | 42.3% | 1,245,567 | 42.8% |
| Professional fees | 577,869 | 18.4% | 536,597 | 18.4% |
| Supplies | 529,494 | 16.8% | 517,172 | 17.8% |
| Rents and leases | 55,586 | 1.8% | 49,841 | 1.7% |
| Rents and leases, related party | 75,869 | 2.4% | 74,164 | 2.5% |
| Other operating expenses | 294,465 | 9.5% | 237,151 | 8.1% |
| Interest expense | 28,905 | 0.9% | 37,421 | 1.3% |
| Depreciation and amortization | 75,510 | 2.4% | 71,663 | 2.5% |
| Loss on extinguishment and modification of debt | — | 0.0% | 1,898 | 0.1% |
| Other non-operating gains | (20,723) | (0.7)% | (255) | 0.0% |
| Total operating expenses | 2,946,324 | 93.8% | 2,771,219 | 95.2% |
| Income before income taxes | 196,190 | 6.2% | 138,747 | 4.8% |
| Income tax expense | 41,524 | 1.3% | 25,935 | 0.9% |
| Net income | 154,666 | 4.9% | 112,812 | 3.9% |
| Net income attributable to noncontrolling interests | 40,333 | 1.3% | 42,995 | 1.5% |
| Net income attributable to Ardent Health, Inc. | $114,333 | 3.6% | $69,817 | 2.4% |
29
The following table provides information on certain drivers of our total revenue:
| Operating Statistics | Three Months Ended June 30, 2025 | % Change | 2024 | Six Months Ended June 30, 2025 | % Change | 2024 |
|---|---|---|---|---|---|---|
| Total revenue (in thousands) | $1,645,280 | 11.9% | $1,470,920 | $3,142,514 | 8.0% | $2,909,966 |
| Hospitals operated (at period end) (1) | 30 | 0.0% | 30 | 30 | 0.0% | 30 |
| Licensed beds (at period end) (2) | 4,281 | (0.1)% | 4,287 | 4,281 | (0.1)% | 4,287 |
| Utilization of licensed beds (3) | 50% | 8.7% | 46% | 50% | 8.7% | 46% |
| Admissions (4) | 41,535 | 6.6% | 38,958 | 82,924 | 7.1% | 77,427 |
| Adjusted admissions (5) | 87,167 | 1.6% | 85,763 | 171,703 | 2.2% | 168,076 |
| Inpatient surgeries (6) | 9,840 | 9.2% | 9,012 | 19,090 | 6.3% | 17,958 |
| Outpatient surgeries (7) | 22,860 | (3.8)% | 23,758 | 44,572 | (3.1)% | 45,981 |
| Emergency room visits (8) | 156,622 | 0.2% | 156,287 | 317,871 | 1.3% | 313,869 |
| Patient days (9) | 194,738 | 8.8% | 179,047 | 390,952 | 9.2% | 358,173 |
| Total encounters (10) | 1,491,905 | 5.9% | 1,408,970 | 2,942,534 | 4.3% | 2,821,442 |
| Average length of stay (11) | 4.68 | 1.7% | 4.60 | 4.71 | 1.7% | 4.63 |
| Net patient service revenue per adjusted admission (12) | $18,581 | 10.2% | $16,859 | $18,001 | 5.7% | $17,028 |
(1) “Hospitals operated (at period end).” This metric represents the total number of hospitals operated by us at the end of the applicable period, irrespective of
whether the hospital real estate is (i) owned by us, (ii) leased by us or (iii) held through a controlling interest in a JV. This metric includes the managed clinical
operations of the hospital at UT Health North Campus in Tyler, Texas (“UT Health North Campus Tyler”), a hospital owned by The University of Texas Health
Science Center at Tyler (“UTHSCT”), an affiliate of The University of Texas System. Since we only manage the clinical operations of UT Health North
Campus Tyler, the financial results of such entity are not consolidated under Ardent Health, Inc.
On April 30, 2024, we closed UT Health East Texas Specialty Hospital, a long-term acute care hospital with 36 licensed patient beds (the “LTAC Hospital”) in
Tyler, Texas. The LTAC Hospital's inventory and fixed assets were transferred or repurposed to be used by our other hospitals.
(2) “Licensed beds (at period end).” This metric represents the total number of beds for which the appropriate state agency licenses a facility, regardless of whether
the beds are actually available for patient use.
(3) “Utilization of licensed beds.” This metric represents a measure of the actual utilization of our inpatient facilities, computed by (i) dividing patient days by the
number of days in each period, and (ii) further dividing that number by average licensed beds, which is calculated by dividing total licensed beds (at period end)
by the number of days in the period, multiplied by the number of days in the period the licensed beds were in existence.
(4) “Admissions.” This metric represents the number of patients admitted for inpatient treatment during the applicable period.
(5) “Adjusted admissions.” This metric is used by management as a general measure of combined inpatient and outpatient volume. Adjusted admissions provides
management with a key performance indicator that considers both inpatient and outpatient volumes by applying an inpatient volume measure (admissions) to a
ratio of gross inpatient and outpatient revenue to gross inpatient revenue. Gross inpatient and outpatient revenue reflect gross inpatient and outpatient charges
prior to estimated contractual adjustments, uninsured discounts, implicit price concessions, and other discounts. The calculation of adjusted admissions is
summarized as follows:
Adjusted Admissions = Admissions x (Gross Inpatient Revenue + Gross Outpatient Revenue)
Gross Inpatient Revenue
(6) “Inpatient surgeries.” This metric represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management, c-
sections, and certain diagnostic procedures are excluded from inpatient surgeries.
(7) “Outpatient surgeries.” This metric represents the number of surgeries performed on patients who have not been admitted to our hospitals. Pain management, c-
sections, and certain diagnostic procedures are excluded from outpatient surgeries.
(8) “Emergency room visits.” This metric represents the total number of patients provided with emergency room treatment during the applicable period.
(9) “Patient days.” This metric represents the total number of days of care provided to patients admitted to our hospitals during the applicable period.
(10) “Total encounters.” This metric represents the total number of events where healthcare services are rendered resulting in a billable event during the applicable
period. This includes both hospital and ambulatory patient interactions.
(11) “Average length of stay.” This metric represents the average number of days admitted patients stay in our hospitals.
(12) “Net patient service revenue per adjusted admission.” This metric represents net patient service revenue divided by adjusted admissions for the applicable
period. Net patient service revenue reflects gross inpatient and outpatient charges less estimated contractual adjustments, uninsured discounts, implicit price
concessions, and other discounts.
Overview of the Three Months Ended June 30, 2025
Total revenue for the three months ended June 30, 2025 increased $174.4 million, or 11.9%, compared to the same prior year
period. The increase in total revenue for the three months ended June 30, 2025 consisted of an increase in net patient service
revenue per adjusted admission of 10.2% and an increase in adjusted admissions of 1.6%, which reflected growth in
admissions and emergency room visits of 6.6% and 0.2%, respectively, partially offset by a decrease in total surgeries of
30
0.2%. The increase in net patient service revenue per adjusted admission was primarily attributable to increased supplemental
program revenue and reimbursement rates compared to the same prior year period.
Total operating expenses increased $134.6 million, but decreased 1.8% as a percentage of total revenue for the three months
ended June 30, 2025 compared to the same prior year period. The decrease in total operating expenses as a percentage of total
revenue was driven primarily by an increase in supplemental program revenue compared to the same prior year period. The
decrease in total operating expense, as a percentage of total revenue, was partially offset by increases in provider assessments
associated with supplemental government programs, equity-based compensation, and professional fees due to higher costs for
hospital-based providers during the three months ended June 30, 2025, compared to the same prior year period.
Comparison of the Three Months Ended June 30, 2025 and 2024
Total revenue — Total revenue for the three months ended June 30, 2025 increased $174.4 million, or 11.9%, compared to
the same prior year period. The increase in total revenue for the three months ended June 30, 2025 consisted of an increase in
net patient service revenue per adjusted admission of 10.2% and an increase in adjusted admissions of 1.6%, which reflected
growth in admissions and emergency room visits of 6.6% and 0.2%, respectively, partially offset by a decrease in total
surgeries of 0.2%. The increase in net patient service revenue per adjusted admission was primarily attributable to increased
supplemental program revenue and reimbursement rates compared to the same prior year period.
Salaries and benefits — Salaries and benefits, as a percentage of total revenue, were 40.8% for the three months ended June
30, 2025 compared to 42.4% for the same prior year period. The decrease in salaries and benefits, as a percentage of total
revenue, was primarily attributable to an increase in supplemental program revenue compared to the same prior year period
partially offset by an increase in equity-based compensation of $11.0 million.
Professional fees — Professional fees, as a percentage of total revenue, were 18.1% for the three months ended June 30, 2025
compared to 18.5% for the same prior year period.
Supplies — Supplies, as a percentage of total revenue, were 16.4% for the three months ended June 30, 2025 compared to
17.6% for the same prior year period. The decrease in supplies, as a percentage of total revenue, was primarily attributable to
an increase in supplemental program revenue compared to the same prior year period.
Rents and leases — Rents and leases were $27.8 million and $25.0 million for the three months ended June 30, 2025 and
2024, respectively.
Rents and leases, related party — Rents and leases, related party, consisted of lease expense related to the Master Lease with
Ventas ("Ventas Master Lease"), under which we lease 10 of our facilities, and other lease agreements with Ventas for certain
medical office buildings. Rents and leases, related party, were $37.8 million and $37.0 million for the three months ended
June 30, 2025 and 2024, respectively.
Other operating expenses — Other operating expenses, as a percentage of total revenue, were 10.0% for the three months
ended June 30, 2025 compared to 7.9% for the same prior year period. Other operating expenses are comprised primarily of
repairs and maintenance, utility, insurance (including professional liability insurance) and provider assessments. The change
in other operating expenses, as a percentage of total revenue, was primarily due to an increase in provider assessments
associated with supplemental government programs during the three months ended June 30, 2025, compared to the same
prior year period.
Interest expense — Interest expense was $14.7 million and $18.2 million for the three months ended June 30, 2025 and 2024,
respectively. On June 26, 2024, we executed an amendment to our ABL Credit Agreement and paid $100.0 million of the
outstanding principal on our Term Loan B Facility. The decrease in interest expense was attributable to the reduction in
average outstanding principal of our Term Loan B Facility during the three months ended June 30, 2025 compared to the
same prior year period.
Loss on extinguishment and modification of debt — In connection with the amendment to our ABL Credit Agreement and
$100.0 million payment on our Term Loan B Facility on June 26, 2024, we incurred a loss on the debt extinguishment of $1.9
million related to the write-off of existing deferred financing costs and original issue discounts for the three months ended
June 30, 2024.
Other non-operating losses (gains) — Other non-operating losses (gains) were a loss of $0.6 million and a gain of $0.3
million for the three months ended June 30, 2025 and 2024, respectively.
31
Income tax expense — We recorded income tax expense of $26.3 million, which equates to an effective tax rate of 21.6%, for
the three months ended June 30, 2025 compared to income tax expense of $15.2 million, which equates to an effective tax
rate of 18.5%, for the same prior year period. The increase in income tax expense was primarily driven by an increase in
income before income taxes attributable to Ardent Health, Inc., which resulted in an increase in taxes at the federal statutory
rate during the three months ended June 30, 2025 compared to the same prior year period. Additionally, the effective tax rate
was further impacted by permanent differences resulting from the disallowance of certain equity-based compensation
incurred during the three months ended June 30, 2025.
Net income attributable to noncontrolling interests — During the three months ended June 30, 2025 and 2024, net income
attributable to noncontrolling interests was $22.8 million and $24.2 million, respectively, and consisted primarily of $22.8
million and $22.4 million, respectively, of net income attributable to minority partners’ interests in hospitals and ambulatory
services that are owned and operated though limited liability companies and consolidated by us. Income from operations
before income taxes related to these limited liability companies ("LLCs") was $68.0 million and $76.7 million for the three
months ended June 30, 2025 and 2024, respectively. For the three months ended June 30, 2024, the remaining portion of net
income attributable to noncontrolling interests consisted of net income attributable to ALH Holdings, LLC’s (a subsidiary of
Ventas, a related party) minority interest in AHP Health Partners, our direct subsidiary, prior to the ALH Contribution in July
Overview of the Six Months Ended June 30, 2025
Total revenue for the six months ended June 30, 2025 increased $232.5 million, or 8.0%, compared to the same prior year
period. The increase in total revenue for the six months ended June 30, 2025 consisted of an increase in net patient service
revenue per adjusted admission of 5.7% and an increase in adjusted admissions of 2.2%, which reflected growth in
admissions and emergency room visits of 7.1% and 1.3%, respectively, partially offset by a decrease in total surgeries of
0.4%. The increase in net patient service revenue per adjusted admission was primarily attributable to increased supplemental
program revenue and reimbursement rates compared to the same prior year period.
Total operating expenses increased $175.1 million, but decreased 1.4% as a percentage of total revenue for the six months
ended June 30, 2025 compared to the same prior year period. The decrease in total operating expenses, as a percentage of
total revenue, was primarily driven by an increase in supplemental program revenue compared to the same prior year period.
The decrease in total operating expense, as a percentage of total revenue, was partially offset by increases in provider
assessments associated with supplemental government programs, equity-based compensation, and professional fees due to
higher costs for hospital-based providers during the six months ended June 30, 2025, compared to the same prior year period.
Comparison of the Six Months Ended June 30, 2025 and 2024
Total revenue — Total revenue for the six months ended June 30, 2025 increased $232.5 million, or 8.0%, compared to the
same prior year period. The increase in total revenue for the six months ended June 30, 2025 consisted of an increase in net
patient service revenue per adjusted admission of 5.7% and an increase in adjusted admissions of 2.2%, which reflected
growth in admissions and emergency room visits of 7.1% and 1.3%, respectively, partially offset by a decrease in total
surgeries of 0.4%. The increase in net patient service revenue per adjusted admission was primarily attributable to increased
supplemental program revenue and reimbursement rates compared to the same prior year period.
Salaries and benefits — Salaries and benefits, as a percentage of total revenue, were 42.3% for the six months ended June 30,
2025 compared to 42.8% for the same prior year period.
Professional fees — Professional fees, as a percentage of total revenue, were 18.4% for the six months ended June 30, 2025
compared to 18.4% for the same prior year period.
Supplies — Supplies, as a percentage of total revenue, were 16.8% for the six months ended June 30, 2025 compared to
17.8% for the same prior year period. The decrease in supplies expense, as a percentage of total revenue, was attributable to
ongoing service line optimization efforts and execution on various supply chain cost reduction initiatives, including improved
inventory management, standardized surgical supply procurement and strategic sourcing. The decrease in supplies, as a
percentage of total revenue, was also attributable to an increase in supplemental program revenue compared to the same prior
year period.
Rents and leases — Rents and leases were $55.6 million and $49.8 million for the six months ended June 30, 2025 and 2024,
respectively.
32
Rents and leases, related party — Rents and leases, related party, consisted of lease expense related to the Ventas Master
Lease and other lease agreements with Ventas for certain medical office buildings. Rents and leases, related party, were $75.9
million and $74.2 million for the six months ended June 30, 2025 and 2024, respectively.
Other operating expenses — Other operating expenses, as a percentage of total revenue, were 9.5% for the six months ended
June 30, 2025 compared to 8.1% for the same prior year period. The increase in other operating expenses, as a percentage of
total revenue, was primarily due to an increase in provider assessments associated with supplemental government programs
during the six months ended June 30, 2025 compared to the same prior year period.
Interest expense — Interest expense was $28.9 million and $37.4 million for the six months ended June 30, 2025 and 2024,
respectively. On June 26, 2024, we executed an amendment to our ABL Credit Agreement and paid $100.0 million of the
outstanding principal on our Term Loan B Facility. The decrease in interest expense was attributable to the reduction in
average outstanding principal of our Term Loan B Facility during the six months ended June 30, 2025 compared to the same
prior year period.
Loss on extinguishment and modification of debt — In connection with the amendment to our ABL Credit Agreement and
$100.0 million payment on our Term Loan B Facility on June 26, 2024, we incurred a loss on the debt extinguishment of $1.9
million related to the write-off of existing deferred financing costs and original issue discounts for the six months ended June
30, 2024.
Other non-operating gains — Other non-operating gains were $20.7 million and $0.3 million for the six months ended June
30, 2025 and 2024, respectively. During the six months ended June 30, 2025, other non-operating gains included a gain on
business interruption insurance proceeds of $21.5 million related to a cybersecurity incident that impacted our operations and
information technology systems in November 2023 (the "Cybersecurity Incident").
Income tax expense — We recorded income tax expense of $41.5 million, which equates to an effective tax rate of 21.2%, for
the six months ended June 30, 2025 compared to income tax expense of $25.9 million, which equates to an effective tax rate
of 18.7%, for the same prior year period. The increase in income tax expense was primarily driven by an increase in income
before income taxes attributable to Ardent Health, Inc., which resulted in an increase in taxes at the federal statutory rate
during the six months ended June 30, 2025 compared to the same prior year period. Additionally, the effective tax rate was
further impacted by permanent differences resulting from the disallowance of certain equity-based compensation incurred
during the six months ended June 30, 2025 compared to same prior year period.
Net income attributable to noncontrolling interests — During six months ended June 30, 2025 and 2024, net income
attributable to noncontrolling interests was $40.3 million and $43.0 million, respectively, and consisted primarily of $40.3
million and $40.1 million, respectively, of net income attributable to minority partners’ interests in hospitals and ambulatory
services that are owned and operated though LLCs and consolidated by us. Income from operations before income taxes
related to these LLCs was $130.6 million and $138.4 million for the six months ended June 30, 2025 and 2024, respectively.
For the six months ended June 30, 2024, the remaining portion of net income attributable to noncontrolling interests consisted
of net income attributable to ALH Holdings, LLC’s (a subsidiary of Ventas, a related party) minority interest in AHP Health
Partners, our direct subsidiary, prior to the ALH Contribution in July 2024.
Supplemental Non-GAAP Information
We have included certain financial measures that have not been prepared in a manner that complies with U.S. generally
accepted accounting principles (“GAAP”), including Adjusted EBITDA and Adjusted EBITDAR. We define these terms as
follows:
Performance Measure
- “Adjusted EBITDA” is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii)
depreciation and amortization expense (or EBITDA), as adjusted to deduct noncontrolling interest earnings, and
excludes the effects of loss on extinguishment and modification of debt; other non-operating losses (gains);
Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; restructuring, exit
and acquisition-related costs; expenses incurred in connection with the implementation of Epic Systems, our
integrated health information technology system; equity-based compensation expense; and loss from disposed
operations. See “Supplemental Non-GAAP Performance Measure.”
33
Valuation Measure
- “Adjusted EBITDAR” is defined as Adjusted EBITDA further adjusted to add back rent expense payable to real
estate investment trusts ("REITs"), which consists of rent expense pursuant to the Ventas Master Lease, lease
agreements associated with the MOB Transactions (as defined below) and a lease arrangement with Medical
Properties Trust, Inc. ("MPT") for Hackensack Meridian Mountainside Medical Center. See “Supplemental Non-
GAAP Valuation Measure.”
Supplemental Non-GAAP Performance Measure
Adjusted EBITDA is a non-GAAP performance measure used by our management and external users of our financial
statements, such as investors, analysts, lenders, rating agencies and other interested parties, to evaluate companies in our
industry.
Adjusted EBITDA is a performance measure that is not prepared in accordance with GAAP and is presented in this Quarterly
Report because our management considers it an important analytical indicator that is commonly used within the healthcare
industry to evaluate financial performance and allocate resources. Further, our management believes that Adjusted EBITDA
is a useful financial metric to assess our operating performance from period to period by excluding certain material non-cash
items and unusual or non-recurring items that we do not expect to continue in the future and certain other adjustments we
believe are not reflective of our ongoing operations and our performance.
Because not all companies use identical calculations, our presentation of the non-GAAP measure may not be comparable to
other similarly titled measures of other companies.
While we believe this is a useful supplemental performance measure for investors and other users of our financial
information, you should not consider the non-GAAP measure in isolation or as a substitute for net income or any other items
calculated in accordance with GAAP. Adjusted EBITDA has inherent material limitations as a performance measure, because
it adds back certain expenses to net income, resulting in those expenses not being taken into account in the performance
measure. We have borrowed money, so interest expense is a necessary element of our costs. Because we have material capital
and intangible assets, depreciation and amortization expense are necessary elements of our costs. Likewise, the payment of
taxes is a necessary element of our operations. Because Adjusted EBITDA excludes these and other items, it has material
limitations as a measure of our performance.
34
The following table presents a reconciliation of Adjusted EBITDA, a performance measure, to net income, determined in
accordance with GAAP:
(in thousands)
| Three Months Ended June 30, 2025 | 2024 | Six Months Ended June 30, 2025 | 2024 | |
|---|---|---|---|---|
| Net income | $95,701 | $66,961 | $154,666 | $112,812 |
| Adjusted EBITDA Addbacks: | ||||
| Income tax expense | 26,291 | 15,222 | 41,524 | 25,935 |
| Interest expense | 14,729 | 18,160 | 28,905 | 37,421 |
| Depreciation and amortization | 39,309 | 36,312 | 75,510 | 71,663 |
| Noncontrolling interest earnings | (22,751) | (24,191) | (40,333) | (42,995) |
| Loss on extinguishment and modification of debt | — | 1,898 | — | 1,898 |
| Other non-operating losses (gains) (a) | 560 | (255) | 777 | (255) |
| Cybersecurity Incident recoveries, net (b) | — | — | (19,705) | — |
| Restructuring, exit and acquisition-related costs (c) | 3,985 | 5,561 | 4,904 | 7,898 |
| Epic expenses (d) | 796 | 426 | 1,284 | 1,015 |
| Equity-based compensation | 11,246 | 226 | 20,509 | 738 |
| Loss from disposed operations | 7 | 1,982 | 33 | 1,986 |
| Adjusted EBITDA | $169,873 | $122,302 | $268,074 | $218,116 |
(a) Other non-operating losses (gains) include losses and gains realized on certain non-recurring events or events that are non-operational in
nature.
(b) Cybersecurity Incident recoveries, net represent insurance recovery proceeds associated with the Cybersecurity Incident, net of
incremental information technology and litigation costs.
(c) Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work
force reductions of $3.3 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, and $3.3 million and
$6.9 million for the six months ended June 30, 2025 and 2024, respectively, (ii) penalties and costs incurred for terminating pre-existing
contracts at acquired facilities of $0.2 million for each of the three months ended June 30, 2025 and 2024, and $0.4 million for each of
the six months ended June 30, 2025 and 2024, and (iii) third-party professional fees and expenses, salaries and benefits, and other
internal expenses incurred in connection with potential and completed acquisitions of $0.5 million and $0.4 million for the three months
ended June 30, 2025 and 2024, respectively, and $1.2 million and $0.6 million for the six months ended June 30, 2025 and 2024,
respectively.
(d) Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology
system. These costs included professional fees of $0.8 million and $0.4 million for the three months ended June 30, 2025 and 2024,
respectively, and $1.3 million and $1.0 million for the six months ended June 30, 2025 and 2024, respectively. Epic expenses do not
include ongoing operating costs of the Epic system.
Liquidity and Capital Resources
Liquidity
Our primary sources of liquidity are available cash and cash equivalents, cash flows from our operations and available
borrowings under our ABL Facilities (as defined below). Our primary cash requirements are our operating expenses, the
service of our debt, capital expenditures on our existing properties, acquisitions of hospitals and other healthcare facilities,
and distributions to noncontrolling interests. We believe the combination of cash flow from operations and available cash and
borrowings will be adequate to meet our short-term liquidity needs. Our ability to make scheduled payments of principal, pay
interest on, or refinance, our indebtedness, pay distributions or fund planned capital expenditures will depend on our ability to
generate cash in the future. This ability is, to a certain extent, subject to general economic, financial, competitive, legislative,
regulatory and other factors that are beyond our control.
At June 30, 2025, we had total cash and cash equivalents of $540.6 million and available liquidity of $835.0 million. Our
available liquidity was comprised of $540.6 million of total cash and cash equivalents plus $294.4 million in available
capacity under the ABL Credit Agreement, which is reduced by outstanding borrowings and outstanding letters of credit. In
June 2024, we amended the ABL Credit Agreement to increase commitments available thereunder by $100.0 million and
extended its maturity date to June 26, 2029. See "Senior Secured Credit Facilities" for additional information. At June 30,
2025, our net leverage ratio, as calculated under our ABL Credit Agreement and Term Loan B Credit Agreement, was 1.2x,
and our lease-adjusted net leverage ratio was 2.7x. Our lease adjusted net leverage is calculated as net debt as of June 30,
2025, plus 8.0x trailing twelve month REIT rent expense as of the end of the second quarter of 2025, divided by the trailing
twelve month Adjusted EBITDAR as of June 30, 2025.
35
Cash Flows
The following table summarizes certain elements of the statements of cash flows (in thousands):
| Six Months Ended June 30, 2025 | 2024 | |
|---|---|---|
| Net cash provided by operating activities | $92,703 | $105,749 |
| Net cash used in investing activities | (69,369) | (70,507) |
| Net cash used in financing activities | (39,490) | (138,281) |
Operating Activities
Cash flows provided by operating activities for the six months ended June 30, 2025 totaled $92.7 million compared to $105.7
million for the same prior year period. The decrease in operating cash flows during the six months ended June 30, 2025 was
impacted by changes in net working capital of $70.1 million. The change in working capital was primarily driven by elevated
cash collections during the same prior year period due to a return to standard billing and collections processing following the
Cybersecurity Incident in November 2023. Working capital was further impacted by an increase in receivables attributable to
supplemental reimbursement programs.
Investing Activities
Cash flows used in investing activities for the six months ended June 30, 2025 totaled $69.4 million compared to $70.5
million for the same prior year period. Capital expenditures for non-acquisitions were $69.1 million and $62.8 million for the
six months ended June 30, 2025 and 2024, respectively.
Financing Activities
Cash flows used in financing activities for the six months ended June 30, 2025 totaled $39.5 million compared to cash flows
used in financing activities of $138.3 million for the same prior year period. Cash flows used in financing activities for the
six months ended June 30, 2025 included distributions paid to noncontrolling interests of $39.5 million, payments of
principal on long-term debt of $2.9 million, and payments of principal on insurance financing arrangements $6.5 million,
which were partially offset by proceeds from insurance financing arrangements of $11.0 million.
Cash flows used in financing activities for the six months ended June 30, 2024 totaled $138.3 million and included payments
of principal on long-term debt of $104.8 million, which includes a prepayment of $100.0 million on the $877.5 million
outstanding borrowings under the Term Loan B Facility. Additionally, cash flows used in financing activities included
distributions paid to noncontrolling interests of $31.7 million, and payments of principal on insurance financing arrangements
of $4.3 million, and debt issuance cost of $2.4 million associated with the amended ABL Credit Agreement which increased
commitments available under the ABL Facilities by $100.0 million. The cash flows used in financing activities were partially
offset by proceeds from insurance financing arrangements of $6.0 million and by proceeds from long-term debt of $1.8
million.
Capital Expenditures
We make significant, targeted investments to maintain and modernize our facilities, introduce new technologies, and expand
our service offerings. We expect to finance future capital expenditures with internally generated and borrowed funds. Capital
expenditures for property and equipment were $69.1 million and $62.8 million for the six months ended June 30, 2025 and
2024, respectively.
Ventas Master Lease
Effective August 4, 2015, we sold the real property for ten of our hospitals to Ventas, which is a related party as, prior to our
IPO, it was a common unit holder of Ardent Health Partners, LLC and owned shares of common stock of AHP Health
36
Partners and had a representative serving on our board of managers. Concurrent with this transaction, we entered into a 20-
year master lease agreement that expires in August 2035 (with a renewal option for an additional ten years) to lease back the
real estate. We lease ten of our hospitals pursuant to the Ventas Master Lease. As of June 30, 2025, following the
consummation of the IPO and the underwriters’ exercise of their option to purchase additional shares, Ventas beneficially
owned approximately 6.5% of our outstanding common stock.
The Ventas Master Lease includes a number of significant operating and financial restrictions, including requirements that we
maintain a minimum portfolio coverage ratio of 2.2x and a guarantor fixed charge coverage ratio of 1.2x and do not exceed a
guarantor net leverage ratio of 6.75x. In addition, the Relative Rights Agreement entered into by and among Ventas, the
5.75% Senior Notes trustee and the administrative agents under our Senior Secured Credit Facilities (as defined below) in
connection with the series of debt transactions completed during 2021 to refinance our then-existing debt, among other
things, (i) sets forth the relative rights of Ventas and the administrative agents with respect to the properties and collateral
related to the Ventas Master Lease and securing our Senior Secured Credit Facilities, (ii) caps the amount of indebtedness
incurred or guaranteed by our subsidiaries that are tenants under the Ventas Master Lease ("Tenants") (together with such
Tenants’ guarantees of the notes and the Senior Secured Credit Facilities and all other indebtedness incurred or guaranteed by
such Tenants) at $375.0 million and (iii) imposes certain incurrence tests on the incurrence of additional indebtedness by such
Tenants and by us.
We recorded rent expense of $37.8 million and $37.0 million for the three months ended June 30, 2025 and 2024,
respectively, and $75.9 million and $74.2 million for the six months ended June 30, 2025 and 2024, respectively, related to
the Ventas Master Lease and other lease agreements for certain medical office buildings with Ventas.
Senior Secured Credit Facilities
Effective July 8, 2021, we entered into the ABL Credit Agreement, which was amended most recently on June 26, 2024. The
ABL Credit Agreement (as so amended) consists of a $325.0 million senior secured asset-based revolving credit facility with
a five year maturity, comprised of (i) a $275.0 million non-UT Health East Texas borrowers tranche (the “non-UT Health
East Texas ABL Facility”) and (ii) a $50.0 million UT Health East Texas borrowers tranche available to our AHS East Texas
Health System, LLC subsidiary and certain of its subsidiaries (the “UT Health East Texas ABL Facility” and, together with
the non-UT Health East Texas ABL Facility, the “ABL Facilities”), each subject to a borrowing base. The ABL Facilities
mature on June 26, 2029.
Effective August 24, 2021, we entered into the Term Loan B Facility. The credit agreement governing the Term Loan B
Facility provided funding up to a principal amount of $900.0 million with a seven-year maturity. Principal under the Term
Loan B Facility was due in quarterly installments of 0.25% of the initial $900.0 million principal amount as of the execution
of the credit agreement (subject to certain reductions from time to time as a result of the application of prepayments), with the
remaining balance due upon maturity of the Term Loan B Facility. Effective June 8, 2023, we amended the Term Loan B
Credit Agreement to replace LIBOR with the Term SOFR and Daily Simple SOFR (each as defined in the amended Term
Loan B Credit Agreement) as the reference interest rate. On June 26, 2024, we prepaid $100.0 million of the $877.5 million
outstanding borrowings under the Term Loan B Facility using cash on hand, which prepaid all remaining required quarterly
principal payments; and no modification was made to the Term Loan B Credit Agreement as a result of this prepayment.
Effective July 19, 2024, pursuant to the terms of the Term Loan B Credit Agreement and as a result of the IPO, the applicable
margin was automatically reduced by 25 basis points to 3.25% over Term SOFR and 2.25% over base rate. On September 18,
2024, we executed an amendment to reprice our Term Loan B Credit Agreement. The repricing reduced the applicable
interest rate by 50 basis points from Term SOFR plus 3.25% to Term SOFR plus 2.75% and from the base rate plus 2.25% to
the base rate plus 1.75%, and it eliminated the credit spread adjustment. No modifications were made to the maturity of the
loans as a result of the repricing and all other terms were substantially unchanged.
We refer to the Term Loan B Facility and the ABL Facilities collectively herein as the “Senior Secured Credit Facilities.”
Subject to certain exceptions, the ABL Facilities are secured by first priority liens over substantially all of our and each
guarantor’s accounts and other receivables, chattel paper, deposit accounts and securities accounts, general intangibles,
instruments, investment property, commercial tort claims and letters of credit relating to the foregoing, along with books,
records and documents, and proceeds thereof (the “ABL Priority Collateral”), and a second priority lien over substantially all
of our and each guarantor’s other assets (including all of the capital stock of the domestic guarantors and first priority
mortgage liens on any fee-owned real property valued in excess of $5,000,000) (the “Term Priority Collateral”). The
obligations of the UT Health East Texas ABL Facility are not secured by the assets of the subsidiaries that are also Tenants
and certain other subsidiaries related to the Tenants. The obligations under the Term Loan B Facility and the ABL Facilities
in excess of the maximum aggregate dollar cap amount permitted to be guaranteed by the Tenants are not secured by the
assets of the Tenants.
37
The Term Loan B Facility is secured by a first priority lien on the Term Priority Collateral and a second priority lien on the
ABL Priority Collateral. Certain excluded assets are not included in the Term Priority Collateral or the ABL Priority
Collateral. The obligations under the Term Loan B Facility and the ABL Facilities in excess of the maximum aggregate dollar
cap amount permitted to be guaranteed by the Tenants are not secured by the assets of the Tenants.
Borrowings under the Term Loan B Facility bear interest at a rate per annum equal to, at our option, either (i) a base rate
determined by reference to the highest of (a) the federal funds effective rate plus 0.50%, (b) the rate last quoted by Bank of
America as the “Prime Rate” in the United States for U.S. dollar loans, and (c) Term SOFR applicable for an interest period
of one month (not to be less than 0.50% per annum), plus 1.00% per annum, in each case, plus an applicable margin, or (ii)
Term SOFR (not to be less than 0.50% per annum) for the interest period selected, in each case, plus an applicable margin.
The applicable margins are as follows:
- under the Term Loan B Credit Agreement, the applicable margin was equal to 2.50% for base rate borrowings and
3.50% for Term SOFR borrowings;
- effective July 19, 2024, pursuant to the terms of the Term Loan B Credit Agreement and as a result of the IPO, the
applicable margin was automatically reduced to 2.25% for base rate borrowings and 3.25% for Term SOFR
borrowings; and
- effective September 18, 2024, we completed a repricing of our Term Loan B Credit Agreement, upon which the
applicable margin was reduced to 1.75% for base rate borrowings and 2.75% for Term SOFR borrowings.
Quarterly installment payments under the Term Loan B Facility are no longer required as a result of our $100.0 million
payment of principal on June 26, 2024, and the remaining principal balance is due upon maturity. The ABL Facilities do not
require installment payments.
At the election of the borrowers under the applicable ABL Facility loan, the interest rate per annum applicable to loans under
the ABL Facilities is based on a fluctuating rate of interest determined by reference to either (i) the base rate plus an
applicable margin or (ii) Term SOFR (not to be lower than 0.00% per annum) for the interest period selected, plus an
applicable margin. The applicable margin is determined based on the percentage of the average daily availability of the
applicable ABL Facility. For the non-UT Health East Texas ABL Facility loan, the applicable margin ranges from 0.5% to
1.0% for base rate borrowings and 1.5% to 2.0% for Term SOFR borrowings. The applicable margin for the UT Health East
Texas ABL Facility loan ranges from 1.5% to 2.0% for base rate borrowings and 2.5% to 3.0% for Term SOFR borrowings.
Subject to certain exceptions (including with regard to the ABL Priority Collateral), thresholds and reinvestment rights, the
Term Loan B Facility is subject to mandatory prepayments with respect to:
- net cash proceeds of issuances of debt by AHP Health Partners or any of its restricted subsidiaries that are not
permitted by the Term Loan B Facility;
- subject to certain thresholds, reinvestment permissions and carve-outs, 100% (with step-downs to 50% and 0%,
based upon achievement of specified senior secured net leverage ratio levels) of net cash proceeds of certain asset
sales;
- subject to certain thresholds, reinvestment permissions and carve-outs, 100% (with step-downs to 50% and 0%,
based upon achievement of specified senior secured net leverage ratio levels) of net cash proceeds of certain
insurance and condemnation events;
- 50% (with step-downs to 25% and 0%, based upon achievement of specified senior secured net leverage ratio levels)
of annual excess cash flow, net of certain voluntary prepayments of secured indebtedness, of AHP Health Partners
and its subsidiaries commencing with the fiscal year ending December 31, 2022; and
- net cash proceeds received in connection with any exercise of the purchase option of the loans by Ventas under the
Relative Rights Agreement.
5.75% Senior Notes due 2029
AHP Health Partners (the "Issuer") issued the 5.75% Senior Notes in an exempt offering pursuant to Rule 144A and
Regulation S under the Securities Act that was completed on July 8, 2021. The terms of the 5.75% Senior Notes, which
mature on July 15, 2029, are governed by an indenture, dated as of July 8, 2021 (the “2029 Notes Indenture”), among the
Issuer, us and certain of the Issuer's wholly-owned domestic subsidiaries, as guarantors, and U.S. Bank, National Association,
as trustee. The 2029 Notes Indenture provides that the 5.75% Senior Notes are general senior unsecured obligations of the
Issuer, which are unconditionally guaranteed on a senior unsecured basis by us and certain subsidiaries of the Issuer.
38
The 5.75% Senior Notes bear interest at a rate of 5.75% per annum, payable semi-annually, in cash in arrears, on January 15
and July 15 of each year, commencing on January 15, 2022.
The Issuer may redeem the 5.75% Senior Notes, in whole or in part, at any time and from time to time, at the redemption
prices set forth below, plus accrued and unpaid interest, if any, to the redemption date, subject to compliance with certain
conditions:
| Date (if redeemed during the 12 month period beginning on July 15 of the years indicated below) | Percentage |
|---|---|
| 2025 | 101.438% |
| 2026 and thereafter | 100.000% |
If the Issuer experiences certain change of control events, the Issuer must offer to repurchase all of the 5.75% Senior Notes
(unless otherwise redeemed) at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if
any, to the repurchase date. If the Issuer sells certain assets and does not reinvest the net proceeds or repay senior debt in
compliance with the 2029 Notes Indenture, it must offer to repurchase the 5.75% Senior Notes at 100% of the principal
amount thereof, plus accrued and unpaid interest, if any, to the repurchase date.
Contractual Obligations and Contingencies
The following table provides a summary of our commitments and contractual obligations for debt, minimum lease payment
obligations under non-cancelable leases and other obligations as of June 30, 2025 (in thousands):
| Payments Due by Period Total | Less than 1 Year | 1-3 Years | 3-5 Years | After 5 Years | |
|---|---|---|---|---|---|
| Long-term debt obligations, with interest | $1,393,523 | $47,777 | $173,485 | $1,156,863 | $15,398 |
| Deferred financing obligations, with interest | 7,295 | 3,642 | 3,189 | 464 | — |
| Operating leases | 2,925,337 | 99,331 | 384,494 | 354,275 | 2,087,237 |
| Estimated self-insurance liabilities | 189,608 | 34,845 | 17,953 | 90,060 | 46,750 |
| Total | $4,515,763 | $185,595 | $579,121 | $1,601,662 | $2,149,385 |
Outstanding letters of credit are required principally by certain insurers and states to collateralize our workers' compensation
programs and self-insured retentions associated with our professional and general liability insurance programs. As of June 30,
2025, we maintained outstanding letters of credit of approximately $33.4 million, which included interest of $2.8 million.
Supplemental Non-GAAP Valuation Measure
Adjusted EBITDAR is a commonly used non-GAAP valuation measure used by our management, research analysts,
investors and other interested parties to evaluate and compare the enterprise value of different companies in our industry.
Adjusted EBITDAR excludes: (1) certain material non-cash items and unusual or non-recurring items that we do not expect
to continue in the future; (2) certain other adjustments that do not impact our enterprise value; and (3) rent expense payable to
our REITs. We operate 30 acute care hospitals, 12 of which we lease from two REITs, Ventas and MPT, pursuant to long-
term lease agreements. Additionally, during 2022, we completed the sale of 18 medical office buildings to Ventas in
exchange for $204.0 million and concurrently entered into agreements to lease the real estate back from Ventas over a 12-
year initial term with eight options to renew for additional five-year terms (the "MOB Transactions"). Our management views
the long-term lease agreements with Ventas and MPT, as well as the MOB Transactions, as more like financing arrangements
than true operating leases, with the rent payable to such REITs being similar to interest expense. As a result, our capital
structure is different than many of our competitors, especially those whose real estate portfolio is predominately owned and
not leased. Excluding the rent payable to such REITs allows investors to compare our enterprise value to those of other
healthcare companies without regard to differences in capital structures, leasing arrangements and geographic markets, which
can vary significantly among companies. Our management also uses Adjusted EBITDAR as one measure in determining the
value of prospective acquisitions or divestitures. Finally, financial covenants in certain of our lease agreements, including the
Ventas Master Lease, use Adjusted EBITDAR as a measure of compliance. Adjusted EBITDAR does not reflect our cash
requirements for leasing commitments. As such, our presentation of Adjusted EBITDAR should not be construed as a
performance or liquidity measure.
39
Because not all companies use identical calculations, our presentation of the non-GAAP measure may not be comparable to
other similarly titled measures of other companies.
While we believe this is a useful supplemental valuation measure for investors and other users of our financial information,
you should not consider the non-GAAP measure in isolation or as a substitute for net income or any other items calculated in
accordance with GAAP. Adjusted EBITDAR has inherent material limitations as a valuation measure, because it adds back
certain expenses to net income, resulting in those expenses not being taken into account in the valuation measure. The
payment of taxes and rent is a necessary element of our valuation. Because Adjusted EBITDAR excludes these and other
items, it has material limitations as a measure of our valuation.
The following table presents a reconciliation of Adjusted EBITDAR, a valuation measure, to net income, determined in
accordance with GAAP:
(in thousands)
| Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | |
|---|---|---|
| Net income | $95,701 | $154,666 |
| Adjusted EBITDAR Addbacks: | ||
| Income tax expense | 26,291 | 41,524 |
| Interest expense | 14,729 | 28,905 |
| Depreciation and amortization | 39,309 | 75,510 |
| Noncontrolling interest earnings | (22,751) | (40,333) |
| Loss on extinguishment and modification of debt | — | — |
| Other non-operating losses (a) | 560 | 777 |
| Cybersecurity Incident recoveries, net (b) | — | (19,705) |
| Restructuring, exit and acquisition-related costs (c) | 3,985 | 4,904 |
| Epic expenses (d) | 796 | 1,284 |
| Equity-based compensation | 11,246 | 20,509 |
| Loss from disposed operations | 7 | 33 |
| Rent expense payable to REITs (e) | 40,674 | 81,561 |
| Adjusted EBITDAR | $210,547 | $349,635 |
(a) Other non-operating losses include losses realized on certain non-recurring events or events that are non-operational in nature.
(b) Cybersecurity Incident recoveries, net represent insurance recovery proceeds associated with the Cybersecurity Incident, net of
incremental information technology and litigation costs.
(c) Restructuring, exit and acquisition-related costs for the three and six months ended June 30, 2025 represent (i) enterprise restructuring
costs, including severance costs related to work force reductions of $3.3 million and $3.3 million, respectively, (ii) penalties and costs
incurred for terminating pre-existing contracts at acquired facilities of $0.2 million and $0.4 million, respectively, and (iii) third-party
professional fees and expenses, salaries and benefits, and other internal expenses incurred in connection with potential and completed
acquisitions of $0.5 million and $1.2 million, respectively.
(d) Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology
system. These costs included professional fees of $0.8 million and $1.3 million for the three and six months ended June 30, 2025,
respectively. Epic expenses do not include ongoing operating costs of the Epic system.
(e) Rent expense payable to REITs for the three and six months ended June 30, 2025 consists of rent expense of $37.8 million and $75.9
million, respectively, related to the Ventas Master Lease and other lease agreements with Ventas for medical office buildings and rent
expense of $2.9 million and $5.7 million, respectively, related to a lease arrangement with MPT for the lease of Hackensack Meridian
Mountainside Medical Center.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with GAAP requires us to make estimates and assumptions that affect
reported amounts and related disclosures. We regularly evaluate the accounting policies and estimates we use. In general, we
base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular
circumstances in which we operate. Actual results may vary from those estimates. We consider our critical accounting
estimates to be those that (i) involve significant judgments and uncertainties, (ii) require estimates that are more difficult for
40
management to determine, and (iii) may produce materially different outcomes under different conditions or when using
different assumptions.
Refer to Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting
Policies and Estimates and our audited consolidated financial statements and notes thereto as of and for the year ended
December 31, 2024 included in the Annual Report for a complete and comprehensive discussion of the accounting policies
and related estimates we believe are most critical to understanding our consolidated financial statements, financial condition
and results of operations and that require complex management judgment and assumptions or involve uncertainties. These
critical accounting estimates include revenue recognition, risk management and self-insured liabilities, and income taxes.
There have been no changes to our critical accounting policies or their application since the date of the Annual Report.
Market risk
As filed, 2,926 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are subject to market risk from exposure to changes in interest rates based on our financing, investing and cash
management activities. We do not, however, hold or issue financial instruments or derivatives for trading or speculative
purposes. At June 30, 2025, the following components of our Senior Secured Credit Facilities bore interest at variable rates at
specified margins above either the agent bank’s alternate base rate or Term SOFR: (i) a $900.0 million, seven-year term loan;
and (ii) a $325.0 million, five-year asset-based revolving credit facility. As of June 30, 2025, we had outstanding variable rate
debt of $767.0 million.
At June 30, 2025, we had interest rate swap agreements with notional amounts totaling $399.8 million and $0.6 million,
expiring June 30, 2026 and June 26, 2029, respectively. Please refer to Note 5 to the Notes to Condensed Consolidated
Financial Statements included within this Quarterly Report for more information on the interest rate swap agreements. Under
the October 2021 Agreements, expiring June 30, 2026, we are required to make monthly fixed rate payments at annual rates
ranging from 1.47% to 1.48% and the counterparties are obligated to make monthly floating rate payments to us based on
one-month Term SOFR, each subject to a floor of 0.39%. On February 5, 2025, we executed new interest rate swap
agreements with an effective date of June 30, 2025 and expiring June 26, 2029. As of the effective date, the notional amounts
totaled $0.6 million, and will accrete up to $400.4 million by June 30, 2026. We are required to make monthly fixed
payments at annual rates ranging from 3.97% to 3.98% and the counterparties are required to make monthly floating rate
payments to the Company based on one-month Term SOFR, each subject to a floor of 0.50%.
Although changes in the alternate base rate or Term SOFR would affect the cost of funds borrowed in the future, we believe
the effect, if any, of reasonably possible near-term changes in interest rates on our variable rate debt on our consolidated
financial position, results of operations or cash flows would not be material. Based on the outstanding borrowings and impact
of the interest rate swaps in place at June 30, 2025, a one percent change in the interest rate would result in a $3.8 million
increase or decrease in our annual interest expense.
We currently believe we have adequate liquidity to fund operations during the near term through the generation of operating
cash flows, cash on hand and access to our Senior Secured Credit Facilities. Our ability to borrow funds under our ABL
Facilities is subject to, among other things, the financial viability of the participating financial institutions. While we do not
anticipate any of our current lenders defaulting on their obligations, we are unable to provide assurance that any particular
lender will not default at a future date.
Controls and procedures
As filed, 1,753 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of
the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures. Based on
this evaluation of our disclosure controls and procedures as of June 30, 2025, our principal executive officer and principal
financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable
assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that
are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the
Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and
forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the
cost-benefit relationship of possible controls and procedures.
41
Changes in Internal Control over Financial Reporting
During the three months ended June 30, 2025, there have been no changes in our internal control over financial reporting, as
such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 306 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to our risk factors that we believe are material to our business, results of operations and
financial condition from the risk factors previously disclosed in the section entitled “Risk Factors” included in the Annual
Report, which are incorporated by reference herein.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $1.65bn | us-gaap:Revenues |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $3.14bn | us-gaap:Revenues |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $26.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $41.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | $73.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | $114.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $0.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | $0.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | $0.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 141,517,661 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 141,111,732 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | $92.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $540.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $1.88bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $5.03bn | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $880.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $3.38bn | us-gaap:Liabilities |
| Long-term debt | At period end2025-06-30 | $1.09bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-06-30 | $19.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-06-30 | $1.25bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001756655-25-000018. Last ingested by Listed: Nov 13, 2026, 16:00 ET. Listed shows no prices and gives no investment advice.